Completed PHASE4 INTERVENTIONAL 2-arm NCT03932721

EXpanded Combination of Evolocumab Plus Empagliflozin on Diabetes: EXCEED-BHS3 Trial (EXCEED-BHS3)

Sponsor: University of Campinas, Brazil

Conditions Diabetes Mellitus, Type 2 Dyslipidemia Associated With Type II Diabetes Mellitus Hypertension Arterial

Updated 6 times since 2019 Last updated: Mar 7, 2023 Started: Oct 1, 2018 Primary completion: Jun 30, 2021 Completion: Oct 30, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Diabetes Mellitus, Type 2 and Dyslipidemia Associated With Type II Diabetes Mellitus and is currently completed. University of Campinas, Brazil leads this study, which shows 6 recorded versions since 2018 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Apr 2023 — Jul 2024 [monthly]

Completed PHASE4

Status: Unknown Status → Completed
Oct 2021 — Apr 2023 [monthly]

Unknown Status PHASE4

Status: Recruiting → Unknown Status
Jan 2021 — Oct 2021 [monthly]

Recruiting PHASE4

▶ Show 1 earlier version

Jun 2019 — Jan 2021 [monthly]

Recruiting PHASE4

First recorded

Oct 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Campinas, Brazil

Data source: University of Campinas, Brazil

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Campinas, Brazil